Literature DB >> 9870206

Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease?

L Thuillier1, B Chadefaux-Vekemans, J P Bonnefont, A Kara, J Aupetit, C Rochette, G Montalescot, M C Couty, P Kamoun, A Ankri.   

Abstract

Whether the 677C-T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene acts as a risk factor for homocysteine-related vascular disease remains a matter of debate. Testing for the 677C-T nucleotide substitution and assay of plasma homocysteine were carried out simultaneously in 69 controls and 113 vascular disease patients from the Paris area. The variant gene frequency as well as the variant homozygous genotype frequency were very similar in controls and patients. Conversely, plasma homocysteine levels were substantially higher in patients than in controls. A slight interaction between the 677C-T MTHFR polymorphism and homocysteinaemia was observed in the patient group only, while a negative correlation between fasting homocysteine and plasma folate levels was found in all individuals homozygous for the 677C-T MTHFR genotype, irrespective of vascular disease. These data suggest that the 677C-T MTHFR polymorphism is not a major determinant of the vascular disease but contributes to increased plasma homocysteine concentration in conjunction with low plasma folate levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870206     DOI: 10.1023/a:1005414617390

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  29 in total

1.  The mutation Ala677-->Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis.

Authors:  V R Arruda; P M von Zuben; L C Chiaparini; J M Annichino-Bizzacchi; F F Costa
Journal:  Thromb Haemost       Date:  1997-05       Impact factor: 5.249

2.  Rapid determination of total homocysteine in plasma.

Authors:  B Chadefaux; M Coudé; M Hamet; J Aupetit; P Kamoun
Journal:  Clin Chem       Date:  1989-09       Impact factor: 8.327

3.  Defects in human methionine synthase in cblG patients.

Authors:  S Gulati; P Baker; Y N Li; B Fowler; W Kruger; L C Brody; R Banerjee
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

4.  Plasma homocyst(e)ine levels in men with premature coronary artery disease.

Authors:  J J Genest; J R McNamara; D N Salem; P W Wilson; E J Schaefer; M R Malinow
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

5.  Factor V Leiden and thermolabile methylenetetrahydrofolate reductase in extreme old age.

Authors:  D C Rees; Y T Liu; M J Cox; P Elliott; J S Wainscoat
Journal:  Thromb Haemost       Date:  1997-11       Impact factor: 5.249

6.  Methylenetetrahydrofolate reductase gene and coronary artery disease.

Authors:  F M van Bockxmeer; C D Mamotte; S D Vasikaran; R R Taylor
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

7.  Radioenzymic determination of homocysteine in plasma and urine.

Authors:  H Refsum; S Helland; P M Ueland
Journal:  Clin Chem       Date:  1985-04       Impact factor: 8.327

8.  Treatment of mild hyperhomocysteinemia in vascular disease patients.

Authors:  D G Franken; G H Boers; H J Blom; F J Trijbels; P W Kloppenborg
Journal:  Arterioscler Thromb       Date:  1994-03

9.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.

Authors:  A M Engbersen; D G Franken; G H Boers; E M Stevens; F J Trijbels; H J Blom
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

10.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

Authors:  P F Jacques; A G Bostom; R R Williams; R C Ellison; J H Eckfeldt; I H Rosenberg; J Selhub; R Rozen
Journal:  Circulation       Date:  1996-01-01       Impact factor: 29.690

View more
  1 in total

1.  Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.

Authors:  G L Booth; E E Wang
Journal:  CMAJ       Date:  2000-07-11       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.